My ePortfolio Register   

WIN Symposium 2017 /
Patient-specific peptide vaccines

26th - 27th Jun 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.07.17
Views: 480

Prof Hans-Georg Rammensee - University of Tübingen, Tübingen, Germany

Prof Rammensee speaks with ecancer at WIN 2017 about assessing the human leukocyte antigen (HLA) rearrangements of cancer patients to determine new targets for therapies.

He summarises the 'ligandome' and its role in directing T cell response, noting mutation-high tumours responding more to checkpoint immunotherapy, and describes how peptides derived from ligand assays could help design cancer vaccines.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence